Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 19:12:676181.
doi: 10.3389/fimmu.2021.676181. eCollection 2021.

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead

Negar Hosseinkhani  1   2   3 , Afshin Derakhshani  1   4 , Mahdi Abdoli Shadbad  2   1 , Antonella Argentiero  4 , Vito Racanelli  5 , Tohid Kazemi  1 , Ahad Mokhtarzadeh  1 , Oronzo Brunetti  4 , Nicola Silvestris  4   5 , Behzad Baradaran  1   3   6
Affiliations
Review

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead

Negar Hosseinkhani et al. Front Immunol. .

Abstract

Immune checkpoints (ICs) have pivotal roles in regulating immune responses. The inhibitory ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of tumoral cells. Therefore, identifying and targeting these inhibitory ICs might be critical for eliminating tumoral cells. V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory IC that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and adaptive anti-tumoral immune responses. Besides, growing evidence indicates that VISTA blockade can enhance the sensitivity of tumoral cells to conventional IC-based immunotherapy, e.g., cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. In this regard, the current study aimed to review the current evidence about the structure and expression pattern of VISTA, its role in TME, the clinicopathological significance of VISTA, and its prognostic values in various cancers. Besides, this review intended to collect the lessons from the recent pre-clinical and clinical studies and propose a strategy to overcome tumor immune-resistance states.

Keywords: VISTA; cancer; immune checkpoints; immune-resistance; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Blocking the interaction between VISTA and VISTA-R can lead to T cell activation and the upregulation of IFN-γ, IL-2, IL-17, CXCL-11, CCL-3, and CCL-5. VISTA, V-domain Ig suppressor of T cell activation; VISTA-R, VISTA-receptor.
Figure 2
Figure 2
The upregulation of VISTA in prostate cancer after anti-CTLA-4 therapy. (A) The expression of CTLA-4 on immune cells, e.g., T cells and macrophages, and its interaction with tumoral cells can attenuate anti-tumoral immune responses. (B) The administration of anti-CTLA-4 can stimulate anti-tumoral immune responses. (C) After anti-CTLA-4 therapy, the upregulation of VISTA inhibits immune cell activation and leads to tumor expansion. (D) Dual VISTA/CTLA-4 blockade can elicit synergistic responses and leads to the elimination of prostate cancer cells. CTLA-4, cytotoxic T-lymphocyte-associated protein-4; VISTA, V-domain Ig suppressor of T cell activation.
Figure 3
Figure 3
CA-170, an orally administered agent, can directly block the interaction of PD-1/PD-L1 and VISTA/VISTA-receptor and reactivate T cells (85). VISTA, V-domain Ig suppressor of T cell activation, PD-1, Programmed cell death protein-1; PD-L1, Programmed death-ligand 1.
See this image and copyright information in PMC

References

    1. Pardoll DM. The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat Rev Cancer (2012) 12(4):252–64. 10.1038/nrc3239 - DOI - PMC - PubMed
    1. Topalian SL, Weiner GJ, Pardoll DM. Cancer Immunotherapy Comes of Age. J Clin Oncol Off J Am Soc Clin Oncol (2011) 29(36):4828–36. 10.1200/JCO.2011.38.0899 - DOI - PMC - PubMed
    1. Lanier LL, O’Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, et al. CD80 (B7) and CD86 (B70) Provide Similar Costimulatory Signals for T Cell Proliferation, Cytokine Production, and Generation of CTL. J Immunol (Baltimore Md 1950) (1995) 154(1):97–105. - PubMed
    1. Rotte A. Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer. J Exp Clin Cancer Res (2019) 38(1):255. 10.1186/s13046-019-1259-z - DOI - PMC - PubMed
    1. Taefehshokr N, Baradaran B, Baghbanzadeh A, Taefehshokr S. Promising Approaches in Cancer Immunotherapy. Immunobiology (2020) 225(2):151875. 10.1016/j.imbio.2019.11.010 - DOI - PubMed

Publication types

MeSH terms